AbbVie gets expanded FDA approval for Qulipta to treat chronic migraine
Qulipta is an oral calcitonin gene-related peptide (CGRP) receptor antagonist, previously approved in the US, as a preventive…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Apr 23
Qulipta is an oral calcitonin gene-related peptide (CGRP) receptor antagonist, previously approved in the US, as a preventive…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
18 Apr 23
The new plants will expand the company’s manufacturing network for active pharmaceutical ingredients and support the growing demand…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
17 Apr 23
Prometheus is a clinical-stage biotechnology company engaged in the discovery, development, and marketing of novel therapeutic and companion…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Apr 23
As part of the clinical trial support agreement, ESSA will sponsor and conduct a Phase 1 trial of…
12 Apr 23
HyQvia is a liquid medicine that contains Recombinant Human Hyaluronidase and immunoglobulins (Ig) from human plasma, infused under…
12 Apr 23
The DNase platform targets neutrophil extracellular traps to improve the outcomes of prevailing treatments, including immunotherapies
10 Apr 23
The two companies decided to conduct a Phase 2 clinical trial of the drug after confirming the safety…
07 Apr 23
Janssen Pharmaceutical revealed that the FDA advised that the primary outcomes from the two phase 3 confirmatory studies…
06 Apr 23
Under the agreement, Proxygen will receive an upfront payment of up to $2.55bn in research, development, and commercial…
05 Apr 23
Arbutus and Genevant accuse Pfizer and BioNTech of using their patented lipid nanoparticle (LNP) delivery technologies without a…